Benzinga | Feb 12, 2021 10:59AM EST

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $186

Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $176 to $186.